Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents.
about
The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infectionsToxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS responseAntibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposalManagement of hemolytic-uremic syndrome in childrenThe Molecular Mechanism of Shiga Toxin Stx2e Neutralization by a Single-domain Antibody Targeting the Cell Receptor-binding DomainApproaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotypeShiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulenceComparison of Shiga toxin production by hemolytic-uremic syndrome-associated and bovine-associated Shiga toxin-producing Escherichia coli isolates.Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection?Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome.Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin subunit BRenal damage and death in weaned mice after oral infection with Shiga toxin 2-producing Escherichia coli strains.Clinical aspects of a nationwide epidemic of severe haemolytic uremic syndrome (HUS) in children.Shiga toxin 2 overexpression in Escherichia coli O157:H7 strains associated with severe human disease.Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS).Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis.Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.[Management of patients with EHEC/HUS. Lessons and perspectives from clinical infectious disease specialists].Disease severity of Shiga toxin-producing E. coli O157 and factors influencing the development of typical haemolytic uraemic syndrome: a retrospective cohort study, 2009-2012.Phenethyl isothiocyanate inhibits shiga toxin production in enterohemorrhagic Escherichia coli by stringent response induction.Global expression of prophage genes in Escherichia coli O157:H7 strain EDL933 in response to norfloxacin.Different classes of antibiotics differentially influence shiga toxin production.Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104:H4 from the 2011 German outbreak.Genotypes and phenotypes of Shiga toxin-producing Escherichia coli (STEC) in Abeokuta, Southwestern NigeriaGnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infectionThe inhibitory effect of colloidal bismuth hydroxide gel on Escherichia coli O157:H7 and on the activity of Shiga toxins.Escherichia coli O157:H7 Shiga toxin-encoding bacteriophages: integrations, excisions, truncations, and evolutionary implicationsGenome analysis of a novel Shiga toxin 1 (Stx1)-converting phage which is closely related to Stx2-converting phages but not to other Stx1-converting phages.Underlying mechanism of antimicrobial activity of chitosan microparticles and implications for the treatment of infectious diseases.Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain.Recycling of Shiga toxin 2 genes in sorbitol-fermenting enterohemorrhagic Escherichia coli O157:NMCollateral effects of antibiotics: carbadox and metronidazole induce VSH-1 and facilitate gene transfer among Brachyspira hyodysenteriae strains.Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.Enteropathogenic and enterohemorrhagic Escherichia coli virulence gene regulation.Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans.Bacteriophages carrying Shiga toxin genes: genomic variations, detection and potential treatment of pathogenic bacteria.Antibiotic-Mediated Modulations of Outer Membrane Vesicles in Enterohemorrhagic Escherichia coli O104:H4 and O157:H7.A Rapid Immunoassay for Detection of Shiga Toxin-Producing Escherichia coli Directly from Human Fecal Samples and Its Performance in Detection of Toxin Subtypes
P2860
Q24623245-8E80274B-7094-4E9B-9B6B-7CFA35B45F5FQ24647531-AB991162-5379-49C2-B29B-451BAD888002Q26827657-514194F8-D701-4289-A99D-CDEFCDA0C95DQ27002576-C2E570C7-5F3F-45A7-B61C-9915F103C8BCQ27684790-A35C490D-0BE8-4B33-8E40-6B3CEA2D3F22Q28087714-2CA89B1C-80BD-42E1-ABA4-389DD5C1FF6DQ30411012-8DD83869-94F0-4B65-A65A-855BE50991D5Q33346383-0E2F93A3-2C55-453B-8127-02270413A5D0Q33346559-472F3A61-49E1-4E96-B3E3-0B4055375174Q33372310-831C6231-E05E-4673-BC03-3B55DA52FAABQ33375389-C5AD25B1-C6D5-4574-89EB-8400F727B072Q33376138-084F2717-F6FE-40B8-AEF8-E3F447B7205FQ33377371-BFB64955-DF92-417B-9DAE-69D062953F2EQ33379972-9EE3BD5F-FFE8-49A0-B54A-BD8501E73AB8Q33396410-00FB8125-8E14-45B6-9A0B-A98E1CB05569Q33396843-C8D5235D-8991-4EF1-B278-11826B1C4DFAQ33399468-F26D75BB-E081-4EDD-95E9-71009950E053Q33400310-114F68C9-F87C-4DC0-AA08-6F243477C760Q33402784-381248B9-56B1-4694-B34D-341BA81615C2Q33405034-55EC913B-C377-4B82-8DC4-9FC164325397Q33429632-38170B79-8C74-4079-BAC4-CB3CC6BF73BEQ33623008-2C0E236A-931D-44C3-8506-FC97FFE7C540Q33856818-95A6DE40-4CC9-43B2-B05D-8060A59C2CA5Q34108726-B4C059AB-5E0F-4A59-98A0-92176D99614EQ34361876-8D3B5E95-6F58-4D66-A82D-580629A353F8Q34387910-FDBAC4CF-159B-4AC1-B0C2-855D14C6810DQ34394719-BCF7E29C-9478-4FB9-8468-738C21A4C128Q34897223-B0E75B1D-FADA-44A1-8D5B-4A780D984921Q35021298-FC726DF1-0EF4-4CC6-B362-7D0751F0927DQ35098340-32D913D3-27D0-4252-9C1D-770E59A12146Q35128249-851667F8-1926-4910-8104-D5353AEFAEA5Q36018770-09FEC820-E0CC-4905-8978-27075499555BQ36420818-CB8EC7A2-9E53-4342-BF31-F47871AE648FQ36672715-A2A7445F-E615-4BF9-8DCF-0456061931E2Q36837884-9D97CB8E-9CF9-4C4B-8207-A9AE8BC6AF04Q36852367-B5097243-E5B9-4C94-A111-6CDEE69F0087Q37077633-22B87491-4BCF-46A8-B429-FF2D8CF70DD6Q37921294-AA10E363-29FB-4694-A3AC-AA2BADF7657CQ38729028-A0E04FD3-CA6C-476E-A1D4-F0EC7A323940Q38735151-4A1C0A19-B84E-4710-B1AD-30FAD3930936
P2860
Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents.
description
1998 nî lūn-bûn
@nan
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Strain-specific differences in ...... tions of antimicrobial agents.
@ast
Strain-specific differences in ...... tions of antimicrobial agents.
@en
type
label
Strain-specific differences in ...... tions of antimicrobial agents.
@ast
Strain-specific differences in ...... tions of antimicrobial agents.
@en
prefLabel
Strain-specific differences in ...... tions of antimicrobial agents.
@ast
Strain-specific differences in ...... tions of antimicrobial agents.
@en
P2093
P356
P1476
Strain-specific differences in ...... ations of antimicrobial agents
@en
P2093
P2888
P304
P356
10.1007/S100960050181
P577
1998-11-01T00:00:00Z
P6179
1041749509